Tariquidar (dihydrochloride)
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) [1].
Product Specifications
CAS Number
[1992047-62-7]
Product Name Alternative
XR9576 (dihydrochloride)
UNSPSC
12352005
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tariquidar-dihydrochloride.html
Solubility
10 mM in DMSO
Smiles
[H]Cl.[H]Cl.O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O
Molecular Formula
C38H40Cl2N4O6
Molecular Weight
719.65
References & Citations
[1]Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128 (2), 403-411.|[2]Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61 (2), 749-758.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Citation 01
J Control Release. 2022 Feb:342:44-52.|ACS Chem Neurosci. 2025 Sep 3;16 (17) :3340-3353.|Antimicrob Agents Chemother. 2015 Nov 30;60 (2) :946-54. |Antioxidants (Basel) . 2021 Jun 11;10 (6) :949.|Antiviral Res. 2021 Sep:193:105124.|bioRxiv. 2025 Jun 24:2025.06.18.660465.|bioRxiv. 2025 Sep 20.|Cell Death Discov. 2021 Aug 5;7 (1) :204.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|Commun Chem. 2024 Jul 13;7 (1) :158.|Crit Rev Anal Chem. 2022;52 (7) :1557-1571.|Eur J Drug Metab Pharmacokinet. 2018 Oct;43 (5) :599-606.|Eur J Med Chem. 2017 Feb 15:127:586-598.|Eur J Med Chem. 2018 Mar 10:147:7-20.|Eur J Pharm Sci. 2019 Jan 15:127:319-329.|Eur J Pharmacol. 2024 Apr 15:969:176431.|Hepatol Commun. 2024 May 2;8 (5) :e0437.|Int J Mol Sci. 2022 Nov 29;23 (23) :14948.|Int J Mol Sci. 2023 Mar 10;24 (6) :5298.|J Biomed Nanotechnol. 2018 Oct 1;14 (10) :1705-1718.|J Cereb Blood Flow Metab. 2016 Aug;36 (8) :1412-23. |J Cereb Blood Flow Metab. 2021 Jul;41 (7) :1634-1646.|J Control Release. 2022 Sep:349:109-117.|J Drug Deliv Sci Technol. May 2022, 103323.|J Nanopart Res. (2018) 20:176.|J Nat Prod. 2022 Dec 23;85 (12) :2746-2752.|Langmuir. 2015 May 12;31 (18) :5115-22. |Mar Drugs. 2022 Nov 25;20 (12) :738.|Mar Drugs. 2022 Sep 23;20 (10) :597.|Mar Drugs. 2023 Jan 14;21 (1) :54.|Mar Drugs. 2023 Mar 14;21 (3) :178.|Mar Drugs. 2024 Aug 30;22 (9) :396.|Mol Pharm. 2019 Mar 4;16 (3) :1282-1293.|Mol Pharm. 2021 Jan 4;18 (1) :416-428.|Pharm Res. 2017 Jan;34 (1) :148-160.|Pharmaceuticals (Basel) . 2023 Feb 24;16 (3) :349.|Pharmaceutics. 2021 Feb 26;13 (3) :306.|PLoS One. 2017 Sep 15;12 (9) :e0183662. |Res Sq. 2025 May 16.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2024 Feb 6.|Research Square Print. 2022 Jul.|RSC Adv. 2016,6, 69083-69093.|Sci Bull. 2016 Apr;61 (7) :552-560.|Sci Rep. 2017 Dec 22;7 (1) :18069.|Sci Rep. 2022 Aug 9;12 (1) :13570.|Small. 2020 Nov;16 (44) :e2004172.|Xenobiotica. 2020 Mar;50 (3) :354-362.|J Cereb Blood Flow Metab. 2020 Jan;40 (1) :150-162.|Mol Imaging Biol. 2019 Apr;21 (2) :257-268. |Mol Pharm. 2020 Sep 8;17 (9) :3477-3486.|Nucl Med Biol. 2018 May:60:29-36.|RWTH Aachen University. 2021 Oct.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15103311 1 Vial
Lentiviral mouse Fndc4 shRNA (UAS) - Lentiviral mouse Fndc4 shRNA (UAS, iRFP) (100)
Ask
View Details 
MBS1217769-01 0.02 mg (E-Coli)
Recombinant Staphylococcus aureus Aspartate carbamoyltransferase (pyrB)
Ask
View Details MBS1217769-02 0.02 mg (Yeast)
Recombinant Staphylococcus aureus Aspartate carbamoyltransferase (pyrB)
Ask
View Details MBS1217769-03 0.1 mg (E-Coli)
Recombinant Staphylococcus aureus Aspartate carbamoyltransferase (pyrB)
Ask
View Details